OOSP1 Inhibitors
OOSP1 inhibitors encompass a range of chemical compounds that intersect with various signaling pathways implicated in the regulation of the OOSP1 protein. The compounds target different nodes within these pathways, providing a multifaceted approach to downregulate OOSP1 activity. For instance, LY294002 and Wortmannin exert their effects by inhibiting PI3K, which is a pivotal element in the PI3K/AKT signaling cascade. The reduction in PIP3 levels following PI3K inhibition leads to diminished AKT phosphorylation. Since AKT is a key regulator of numerous cellular processes, including those that might control OOSP1, its inhibition can result in the decreased activity of OOSP1. Similarly, Dactolisib and Everolimus exert an inhibitory effect on both PI3K and mTOR pathways, which are intrinsically linked to cellular growth, proliferation, and survival signals. The duality of this inhibition not only impacts the PI3K/AKT axis but also the mTOR signaling, potentially leading to a comprehensive downregulation of OOSP1 activity if it is regulated by these pathways.
Additionally, PD98059 and U0126 specifically target MEK1/2 within the MAPK/ERK pathway, an important conduit for the transmission of cell growth and differentiation signals. Inhibition of MEK, and thereby the suppression of ERK phosphorylation, could lead to a decrease in OOSP1 activity, presuming that OOSP1 is a downstream effector in this signaling route.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K. OOSP1 activity is related to PIK3 signaling; inhibition of PI3K by LY294002 will reduce the phosphorylation of AKT, leading indirectly to the reduced activation of downstream targets which may include OOSP1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor. If OOSP1 is downstream of mTOR, rapamycin would inhibit mTORC1 complex formation, leading to decreased OOSP1 activity if it is mTOR-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK1/2. By inhibiting MEK, PD98059 prevents the activation of ERK1/2, potentially decreasing OOSP1 activity if it is regulated by the MAPK/ERK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that prevents the activation of MAPK/ERK kinase. If OOSP1 is modulated by the MAPK pathway, U0126 would lead to a reduction in its activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can prevent the degradation of proteins regulated by the ubiquitin-proteasome system. If OOSP1 is regulated through proteasomal degradation, bortezomib would increase its substrate levels, potentially inhibiting OOSP1 activity indirectly. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A reversible proteasome inhibitor, which may lead to the accumulation of ubiquitinated proteins. If OOSP1’s activity is regulated by the degradation of certain proteins, MG132 could inhibit its function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A SERCA pump inhibitor that disrupts calcium homeostasis. If OOSP1 activity is calcium-dependent, thapsigargin-induced elevation of cytosolic calcium could inhibit OOSP1 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. If OOSP1 is part of a signal transduction pathway involving these kinases, imatinib could indirectly inhibit OOSP1 activity. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
A dual PI3K and mTOR inhibitor. By inhibiting both PI3K and mTOR pathways, dactolisib would reduce AKT phosphorylation and mTOR signaling, potentially decreasing OOSP1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A potent PI3K inhibitor that acts irreversibly. By inhibiting PI3K, wortmannin would decrease AKT activity and subsequently could reduce OOSP1 activity if it is AKT-dependent. | ||||||